Infective Endocarditis by Pseudomonas Species Following Percutaneous Transluminal Mitral Commissurotomy

Department of Cardiology, National Institute of Cardiovascular Disease, Dhaka, Bangladesh.

Abstract:
Infective mitral valve endocarditis developed in a 35-year-old male patient after a percutaneous transluminal mitral commissurotomy (PTMC). The echocardiogram demonstrated vegetation in the anterior leaflet of the mitral valve and blood culture showed growth of Pseudomonas species which was sensitive to Ceftazidime, Ciprofloxacin, Cotrimoxazole and Imipenem and resistant to Amikacin, Ceftriaxone, Gentamycin and Nitilmycin. The patient underwent treatment with intravenous ceftazidime and ciprofloxacin for six weeks and patient improved significantly and got cure of the disease. Infective mitral valve endocarditis should be recognized as a potentially lethal complication after PTMC. The important measures to prevent bacteremia during PTMC and the appropriate role of antibiotics and operation are discussed.

(Cardiovasc. j. 2010; 2(2) : 252-255)

Keywords: PTMC, Infective endocarditis.

Address of Correspondence: Dr. Md. Toufiqur Rahman, Department of Cardiology, NICVD, Dhaka, Bangladesh.
Investigations showed, Hb-10.7gm/dl, total count 11.800/cu.mm with N-76%, L-20%, E-3% B-00%, ESR-90mm in 1st hr, CRP-18mg/dl, blood culture and sensitivity tests were done for several times. Previously four blood cultures were negative; blood culture done on 16.09.09 revealed Pseudomonas species and sensitive to Ceftazidime, Ciprofloxacin, Cotrimoxazole and Imipenem and resistant to Amikacin, Ceftaxone, Gentamycin and nitilmycin. Echocardiography showed vegetation on tip of anterior mitral leaflet of mitral valve (Fig-1).

After six weeks of intravenous Ceftazidime and intravenous Ciprofloxacin patient improved significantly, feeling of wellbeing improved, fever subsided, appetite increased, ESR reduced. Follow up echocardiography after 8 weeks revealed no vegetations at tip of anterior mitral leaflet.

Fig-1: Vegetation in AML of Mitral Valve.

Discussion:
Most (95%) patients with P. aeruginosa endocarditis have abused intravenous drugs, and nearly all Intravenous Drug Abusers (IDUs) have abused Tripenlennamine and Pentazocine (“T’s and blues”). The male: female ratio is 2.5:1, and the mean age is 30 years. The organism affects normal valves in most cases. Major embolic phenomena, inability to sterilize valves, neurological complications (53%), ring and annular abscesses, splenic abscesses, bacteremtic relapses, and rapidly progressive CHF are common. Ecthyma gangrenosum, the necrotizing cutaneous lesion characteristic of Pseudomonas bacteremia, has occasionally been noted, especially in cases of IE caused by P (Burkholderia) cepacia. The disease carries the highest mortality rate in patients >30 years of age (73% versus 33% in younger patients) when the duration of illness is <5 days (which increases mortality from 41% to 76%) and when there is left-sided cardiac involvement. Because of the gloomy outlook and frequent complications, many authorities recommend early surgery for left-sided Pseudomonas endocarditis. In contrast, high-dose regimens of Antipseudomonal Penicillins combined with Aminoglycosides have had a salutary effect in a majority of patients with isolated right-sided Pseudomonal IE.

Medical therapy may be successful in P. aeruginosa IE involving the right side of the heart in 50% to 75% of cases. If the disease is refractory to antibiotics, then partial tricuspid valvulectomy or “vegetectomy” without valve replacement is indicated. Although valve replacement often is necessary for curing left-sided IE caused by P aeruginosa, results in a series of 10 patients (7 with left-sided involvement alone or in combination with tricuspid disease) suggest that medical therapy alone is occasionally curative. Studies in animals with experimental Pseudomonas endocarditis offer a potential explanation for these disparate results: The penetration into vegetations and the time during which antibiotic concentrations exceeded the MBC were both significantly greater with tricuspid than with aortic vegetations for both Ceftazidime and Tobramycin. Problems have emerged with all potential regimens in animal models of P. aeruginosa IE, including failure of β-lactam (eg, Ceftazadime) therapy as a result of constitutive hyperproduction of type β-lactamase by isolates within valve vegetations in animal models and clinically; isolates demonstrating Aminoglycoside resistance caused by permeability defects that emerge during therapy; absence of a postantibiotic effect of β-lactams against P. aeruginosa in vivo, thus necessitating frequent (or continuous) drug administration; and reduced host mediated clearance of mucoid strains from the valvular vegetation resulting from alginate exopolysaccharide. On the basis of clinical experience, however, the preferred regimen for IE caused by P. aeruginosa is high-dose tobramycin (8 mg/kg per day IV or intramuscularly in once-daily doses) with maintenance of peak and
trough concentrations of 15 to 20 μgm/mL and ≤2 μgm/mL, respectively, in combination with either an extended-spectrum penicillin (eg, Ticarcillin, Piperacillin, Azlocillin) or Ceftazidime or Cefepime in full doses (Class IIa, Level of Evidence: B). The toxicity associated with this regimen is surprisingly low; combination treatment should be given for a minimum of 6 weeks. The use of Quinolones (in combination with an Aminoglycoside) for the treatment of *Pseudomonas* endocarditis appears promising, based on favorable results in animal models and humans, but the development of stepwise resistance during therapy may limit the efficacy of this class of drugs in the future. On the basis of limited experimental data, Ceftazidime-Tobramycin is preferred over Aztreonam-Tobramycin for this disease. Approximately 7 cases of *P. aeruginosa* endocarditis have been successfully treated with imipenem plus an aminoglycoside, but the potential for the development of resistance exists with any of these regimens.

Y. Moriyama et al reported first case of Infective mitral valve endocarditis after percutaneous transvenous mitral commissurotomy in 1995. Bacteremia occurs very infrequently during routine diagnostic cardiac catheterization. According to the literature, infective endocarditis occurred in only 3 of 12,367 cases evaluated in the cooperative study on cardiac catheterization. The therapeutic effectiveness of PTMC is, however, based on mechanical fracturing of the fused commissure. The site of damage induced by balloon dilatation on an already compromised valve would be ideal for bacterial implantation. Animal experiments using rabbits have demonstrated that bacteremia in association with catheter induced endothelial damage may result in endocarditis.

It must therefore be underscored that a sterile technique for the PTMC procedure and prompt removal of the intra-venous catheters should decrease the incidence of bacteremia. All patients undergoing PTMC should be treated with prophylactic antibiotics, achieving therapeutic serum bacteriocidal levels in the periprocedure period. This may be especially important in immunocompromised patients. Infective endocarditis after interventional catheter procedures is a rare event; however, whenever this complication is suspected, echocardiography should be performed to detect any new lesions on the infected valve such as vegetation. Prompt surgical treatment with valvuloplasty or replacement of the infected valve is indicated in patients who failed to respond to the appropriate antibiotic treatment.

**References:**


